

**Enterprise P&T Meeting  
Committee Meeting Minutes  
May 2, 2022**

**Voting Members Present**

Antypas, Christopher, PharmD	Davis, Tracey, PharmD	Hockmuth, Robert, MD	Muller, Betty, MD	Robinson, Michelle, PharmD
Batluck, David, DO	Elebra, Rogers, PharmD	Kryger, Emily, PharmD	Orr, Lavdena, MD	Smith, Kirby, MD
Brinley, Floyd (John), MD	Feconda, Fury, PharmD	Martin, Kelly, PharmD	Peters, Eric, PharmD	Wear, Wayne, PharmD
Caton, Kirt, MD	Higgins, Lily, MD	McAllister, Susan, MD	Peterson, Andrew, PharmD	Whitfield, Rani, MD
Cooper, Don, MD	Himmelstein, Bruce, MD	Michael, Kendra, MD	Petkash, David, MD	Wise, Rodney, MD

**Excused Voting Members**

Beam, Donald, MD		

**Invited Guests Present**

Broussard, Rachel			
Guerriero, Monica			

Issue	Discussion	Conclusion/Results	Vote	Action/ Person Responsible
1. Call to Order	The meeting was called to order at 6:04 PM EST Welcomed all external and internal participants.	Informational Only		Bruce Himelstein
2. Conflict of Interest Disclosure	No conflicts announced	Informational Only		Sheena Cherian
[REDACTED]		[REDACTED]		[REDACTED]
4. Review and approval of January P&T and February Proxy minutes		Informational Only Motion: Don Cooper Second: Andrew Peterson		Sheena Cherian
[REDACTED]				
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>			
--	---	--	--	--

	[REDACTED]			
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]
	[REDACTED]	[REDACTED]		[REDACTED]

<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>		
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>

	[REDACTED]	[REDACTED]		
<b>6. New Business</b>				
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]

	<p>[REDACTED]</p> <p>[REDACTED]</p>			
--	-------------------------------------	--	--	--



	<p>[REDACTED]</p>			
<p>[REDACTED]</p>	<p>[REDACTED]</p>	<p>[REDACTED]</p>		<p>[REDACTED]</p>

	[REDACTED]			
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]

Continuous Glucose Monitors

**PerformRx makes the following recommendation:**

[REDACTED]

**Committee approved as recommended**

**Motion:** Wayne Weart  
**Second:** Andrew Peterson

PerformRx will update the criteria and formulary/PDL with any changes

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p><b>CHC:</b></p> <ul style="list-style-type: none"> <li>• Allow for prescribing by or in consultation with a certified diabetic educator or an obstetrician/gynecologist</li> <li>• Allow approval for all gestational diabetic members using insulin</li> </ul> <p>[REDACTED]</p> <p>[REDACTED]</p>			
<p>Insulin Pumps</p>	<p><b>PerformRx makes the following recommendation:</b></p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p><b>Committee approved as recommended</b></p> <p><b>Motion:</b> Wayne Weart  <b>Second:</b> Andrew Peterson</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p><b>[REDACTED] CHC:</b></p> <ul style="list-style-type: none"><li>• Allow for prescribing by or in consultation with an obstetrician/gynecologist or certified diabetic educator</li></ul> <p>[REDACTED]</p>			
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p>			
Rituximab	<p><b>PerformRx makes the following recommendation:</b></p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p><b>Committee approved as recommended</b></p> <p><b>Motion:</b> Wayne Weart <b>Second:</b> Andrew Peterson</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>			
--	---	--	--	--

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>			
--	---	--	--	--







[REDACTED]









**[REDACTED] CHC**

- Require a trial and failure with 2 preferred biologic agents for rheumatoid arthritis instead of all 4 to align with standard rheumatoid arthritis criteria for non-preferred agent requests
- For rheumatoid arthritis, update preferred biosimilar to Ruxience instead of Truxima now that Ruxience is indicated for rheumatoid arthritis and is more cost-effective
- Minor language changes for clarity
- Align with updated guidelines for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), remove cyclophosphamide as a previous step prior to rituximab and allow for initial use with rituximab in severe disease


[REDACTED]


				
				

				
--	---	--	--	--

				
				
<b>7. Drug Reviews:</b>				
<b>A. Therapeutic Class:</b>				
				

	<p>[REDACTED]</p>			
--	-------------------	--	--	--

				
--	---	--	--	--








	<p>[REDACTED]</p>			
--	-------------------	--	--	--








				
--	---	--	--	--

				
--	---	--	--	--

				
--	---	--	--	--

				
Contraceptive Foams and Devices	<p><b>PerformRx makes the following recommendation:</b></p>    <b>CHC:</b> <ul style="list-style-type: none"><li>• Make no changes to the formulary status of the products in this class</li></ul>	<p><b>Committee approved as recommended</b></p> <p><b>Motion:</b> Kirt Katon <b>Second:</b> Kelly Martin</p>		PerformRx will update the criteria and formulary/PDL with any changes

				
<p>Potassium Replacement</p>	<p align="center"><b>PerformRx makes the following recommendation:</b></p>    <p><b>CHC:</b></p> <ul style="list-style-type: none"> <li>• Make no changes to the formulary status of the medications in this class</li> </ul> 	<p align="center"><b>Committee approved as recommended</b></p> <p><b>Motion:</b> Kirt Caton  <b>Second:</b> Kelly Martin</p>		<p align="center">PerformRx will update the criteria and formulary/PDL with any changes</p>

<b>B. Single Products:</b>		:		
Provence	<p><b>PerformRx makes the following recommendation:</b></p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p><b>Committee approved as recommended</b></p> <p><b>Motion:</b> Wayne Weart <b>Second:</b> David Batluck</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <p><b>CHC:</b></p> <ul style="list-style-type: none"><li>• Make no changes to the formulary status of Proveng</li><li>• Approve the Dendritic Cell Tumor Peptide Immunotherapy prior authorization criteria with no changes</li></ul> <p>[REDACTED]</p>			
Sucraid	<p><b>PerformRx makes the following recommendation:</b></p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p><b>Committee approved as recommended</b></p> <p><b>Motion:</b> Wayne Weart <b>Second:</b> David Batluck</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p><b>[redacted] CHC:</b></p> <ul style="list-style-type: none"><li>• Make no changes to the formulary status of Sucraid (sacrosidase)</li></ul> <p>[redacted]</p> <ul style="list-style-type: none"><li>• [redacted]</li></ul>			
<p>Ridaura.</p>	<p><b>PerformRx makes the following recommendation:</b></p> <p>[redacted]</p> <p>[redacted]</p> <p>[redacted]</p> <p><b>[redacted] CHC:</b></p> <ul style="list-style-type: none"><li>• Make no change to the formulary status of Ridaura (auranofin)</li></ul> <p>[redacted]</p>	<p><b>Committee approved as recommended</b></p> <p><b>Motion:</b> Wayne Weart <b>Second:</b> David Batluck</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>



Leqvio

**PerformRx makes the following recommendation:**

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

**[REDACTED] CHC:**

- Keep Leqvio to tier 4 of the formulary with a prior authorization requirement
- Approve the Leqvio prior authorization criteria as a new policy

Committee approved as recommended

**Motion:** Wayne Weart  
**Second:** David Batluck

PerformRx will update the criteria and formulary/PDL with any changes

	[REDACTED]			
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>			
Recorlev	<p><b>PerformRx makes the following recommendation:</b></p> <p>[REDACTED]</p>	<p><b>Committee approved as recommended</b></p> <p><b>Motion:</b> Wayne Weart <b>Second:</b> David Batluck</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p><b>[REDACTED] CHC:</b></p> <ul style="list-style-type: none"><li>• Add Recorlev (levoketoconazole) to Tier 4 with a prior authorization requirement</li><li>• Approve the newly developed Adrenal Enzyme Inhibitors for Cushing's Syndrome prior authorization criteria</li></ul> <p>[REDACTED]</p> <p>[REDACTED]</p>			
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>		<p>[REDACTED]</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>		
Adbry	<p><b>PerformRx makes the following recommendation:</b></p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p><b>Committee approved as recommended</b></p> <p><b>Motion:</b> Kirt Caton <b>Second:</b> Chris Meny</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p><b>[REDACTED] CHC:</b></p> <ul style="list-style-type: none"><li>• Add Adbry (tralokinumab-ldrm) to tier 4 with a prior authorization requirement</li><li>• Approve the newly developed Adbry prior authorization criteria</li></ul> <p>[REDACTED]</p> <p>[REDACTED]</p>			
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>			
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>



	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>			
Tezpire	<p><b>PerformRx makes the following recommendation:</b></p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p><b>Committee approved as recommended</b></p> <p><b>Motion:</b> Kirt Caton <b>Second:</b> Chris Meny</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>



	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] <b>CHC:</b></p> <ul style="list-style-type: none"><li>• Add Tezspire (tezpelumab-ekko) to Tier 4 and adding a prior authorization requirement</li><li>• Approve the newly developed Tezspire prior authorization criteria</li></ul> <p>[REDACTED]</p> <p>[REDACTED]</p>			
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>			
--	---	--	--	--

	<p>[REDACTED]</p>			
--	-------------------	--	--	--

				
Ryplazim	<p><b>PerformRx makes the following recommendation:</b></p> 	<p><b>Committee approved as recommended</b></p> <p><b>Motion:</b> Kirt Caton <b>Second:</b> Chris Meny</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>			
--	---	--	--	--



[REDACTED]

**[REDACTED] CHC:**

- Make no changes to the formulary status of Ryplazim (plasminogen human-tmvh) (Remain Tier 4-PA)
- Approve the updated Agents for Atopic Dermatitis prior authorization criteria
- Approve the newly developed Treatments for Plasminogen Deficiency Type 1 (PLD1) prior authorization criteria

[REDACTED]

<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>
-------------------	---	-------------------------------------	--	-------------------

				
Voxzogo	<p><b>PerformRx makes the following recommendation:</b></p> 	<p><b>Committee approved as recommended</b></p> <p><b>Motion:</b> Kirt Caton <b>Second:</b> Chris Meny</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>



	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p><b>[REDACTED] CHC:</b></p> <ul style="list-style-type: none"> <li>• Make no changes to the formulary status of Voxzogo (vosoritide) (Remaining T4-PA)</li> <li>• Approve the newly developed Voxzogo prior authorization criteria</li> </ul> <p>[REDACTED]</p>			
Vyvgart	<p><b>PerformRx makes the following recommendation:</b></p> <p>[REDACTED]</p>	<p><b>Committee approved as recommended</b></p> <p><b>Motion:</b> Kirt Caton <b>Second:</b> Chris Meny</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

**[REDACTED] CHC:**

- Make no changes to the formulary status of Vyvgart (efgartimod alfa-fcab) (Remaining T4-PA)
- Approve the newly developed Vyvgart prior authorization criteria

[REDACTED]

	<p>[REDACTED]</p>			
<p>8. New Products</p>	<p><b>PerformRx makes the following recommendation:</b></p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p><b>Add to Specialty Tier with a PA requirement for [REDACTED] CHC [REDACTED]:</b></p> <ul style="list-style-type: none"><li>• Enjaymo</li><li>• Carvykti</li><li>• Kimmtrak</li></ul>	<p><b>Committee approved as recommended</b></p> <p><b>Motion:</b> Wayne Weart <b>Second:</b> Donald Cooper</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

- Opdualag
- Pemfexy
- Pyrukynd

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

**Add to Tier 3 with an AL ( $\geq 19$ ) for**

**[REDACTED] CHC [REDACTED]:**

- Prehevbrio
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]

[REDACTED]

Remain non-formulary/non-preferred for  
[REDACTED] CHC [REDACTED]:

- Akovaz
- Dartisla
- KeraStat
- Korsuva
- Quadracel
- Rezipres
- Seglentis
- SilvaSorb
- Vasostrict

[REDACTED]

9. Prior Authorization  
Criteria Review

<p>A. Prior Authorization Criteria Annual Review</p>				
<p>Amyotrophic Lateral Sclerosis (ALS agents)</p>	<p><b>PerformRx makes the following recommendation:</b></p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] <b>CHC:</b></p> <ul style="list-style-type: none"> <li>• Add requirement that member must have a diagnosis of ALS</li> </ul>	<p><b>Committee approved as recommended</b></p> <p><b>Motion:</b> Bruce Himelstein <b>Second:</b> Kelly Martin</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<ul style="list-style-type: none"><li>• Minor language changes</li></ul> <p>[Redacted]</p>			
Atovaquone Suspension (Mepron)	<p><b>PerformRx makes the following recommendation:</b></p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p><b>CHC:</b></p> <ul style="list-style-type: none"><li>• Add criteria for the treatment and prevention of <i>toxoplasma gondii</i> encephalitis since atovaquone is included as an alternative agent in the guidelines</li></ul>	<p><b>Committee approved as recommended</b></p> <p><b>Motion:</b> Bruce Himelstein <b>Second:</b> Kelly Martin</p>		PerformRx will update the criteria and formulary/PDL with any changes



	[REDACTED]			
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]

Complement Inhibitors

**PerformRx makes the following recommendation:**

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

**[REDACTED] CHC:**

- Allow dose that is in line with compendia in addition to FDA-approved dose for reauthorization requests

[REDACTED]

**Committee approved as recommended**

**Motion:** Bruce Himmelstein  
**Second:** Kelly Martin

PerformRx will update the criteria and formulary/PDL with any changes

	[REDACTED]			
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]

	<p>[REDACTED]</p> <p>[REDACTED]</p>			
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]




[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

				
Oxlumo	<p><b>PerformRx makes the following recommendation:</b></p>  	<p><b>Committee approved as recommended</b></p> <p><b>Motion:</b> Donald Cooper <b>Second:</b> Kelly Martin</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>			
--	---	--	--	--



[REDACTED]

**[REDACTED] CHC:**

- Allow confirmation of diagnosis via liver biopsy as genetic testing may not be available
- Allow metabolic confirmation of diagnosis via urinary oxalate:creatinine ratio due to difficulty obtaining 24 hr urine collection and its use in pivotal trials
- Remove requirement member must be concurrently taking potassium citrate and has attempted increased fluid intake as these are standard medical management and does not encompass all available options

[REDACTED]

Palynziq

**PerformRx makes the following recommendation:**

[REDACTED]

[REDACTED]

[REDACTED]

**Committee approved as recommended**

**Motion:** Donald Cooper  
**Second:** Kelly Martin

PerformRx will update the criteria and formulary/PDL with any changes

[REDACTED]

[REDACTED]

**[REDACTED] CHC:**

- Language changes for clarity
- Update definition of non-responder to Kuvan to align with package labeling
- Remove non-responder definition for Palynziq to align with package labeling
- Update reauthorization criteria to allow for members demonstrating any reduction in blood phenylalanine levels

[REDACTED]

	[REDACTED]			
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]

Primary Hemophagocytic  
Lymphohistiocytosis (HLH)  
Agents

**PerformRx makes the following  
recommendation:**

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] **CHC:**

- Remove requirement that member does not have secondary HLH

**Committee approved as  
recommended**

**Motion:** Donald Cooper  
**Second:** Kelly Martin

PerformRx will update the  
criteria and formulary/PDL  
with any changes

	<ul style="list-style-type: none"><li>Remove attestation that HSCT has not yet been initiated in reauthorization criteria</li></ul> <p>[Redacted]</p>			
Somatostatin Analogues	<p><b>PerformRx makes the following recommendation:</b></p> <p>[Redacted]</p>	<p><b>Committee approved as recommended</b></p> <p><b>Motion:</b> Donald Cooper <b>Second:</b> Kelly Martin</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

				
--	---	--	--	--

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]



**CHC:**

- Update title to include growth hormone receptor agonists
- Include Somavert in the criteria allowing for its approval when there has been an inadequate response to therapy with a somatostatin analog for acromegaly
- Remove Bynfenzia from the criteria as it is no longer marketed or available
- Update criteria to require surgical treatment prior to use of a somatostatin analog and removing option for radiation to align with guideline recommendations
- Require trial and failure of a dopamine agonist only in patients with mild disease to align with guideline recommendations

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]

	[REDACTED]	[REDACTED]		
B. Prior Authorization Criteria Annual Review without Clinical Changes				
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>			
<p>Antisense Oligonucleotides for Duchenne Muscular Dystrophy</p>	<p><b>PerformRx makes the following recommendation:</b></p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p><b>Committee approved as recommended</b></p> <p><b>Motion:</b> Donald Cooper <b>Second:</b> Tracey Davis</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p><b>CHC:</b></p> <ul style="list-style-type: none"><li>• Approve the Antisense Oligonucleotides for Duchenne Muscular Dystrophy prior authorization criteria with no clinical changes</li></ul> <p>[REDACTED]</p>			
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p>			
<p>B-Cell Maturation Antigen (BCMA) Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy</p>	<p><b>PerformRx makes the following recommendation:</b></p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p><b>Committee approved as recommended</b></p> <p><b>Motion:</b> Donald Cooper <b>Second:</b> Tracey Davis</p>		<p>No changes</p>

	<p>[REDACTED]</p> <p><b>CHC:</b></p> <ul style="list-style-type: none"><li>• Approve the B-Cell Maturation Antigen (BCMA) Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy prior authorization criteria with no clinical changes</li></ul> <p>[REDACTED]</p>			
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>



Diagnosis Code Requirement

**PerformRx makes the following recommendation:**

**Committee approved as recommended**

No Changes

[REDACTED]

**Motion:** Donald Cooper  
**Second:** Tracey Davis

[REDACTED]

**[REDACTED] CHC:**

- Approve the Diagnosis Code Requirement prior authorization criteria with no clinical changes

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>			
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>

	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>			
<p>Insulin-Like Growth Factor-1 Receptor (Igf-1r) Antagonists For Thyroid Eye Disease</p>	<p><b>PerformRx makes the following recommendation:</b></p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	<p><b>Committee approved as recommended</b></p> <p><b>Motion:</b> Donald Cooper <b>Second:</b> Tracey Davis</p>		<p>No Changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p><b>CHC:</b></p> <ul style="list-style-type: none"> <li>• Approve the Insulin-Like Growth Factor-1 Receptor (Igf-1r) Antagonists For Thyroid Eye Disease prior authorization criteria with no clinical changes</li> </ul> <p>[REDACTED]</p>			
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>
<p>Ketamine</p>	<p><b>PerformRx makes the following recommendation:</b></p>	<p><b>Committee approved as recommended</b></p>		<p>No Changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p><b>CHC:</b></p> <ul style="list-style-type: none"> <li>• Approve the Ketamine prior authorization criteria with no clinical changes</li> </ul> <p>[REDACTED]</p>	<p><b>Motion:</b> Donald Cooper  <b>Second:</b> Tracey Davis</p>		
<p>Kuvan</p>	<p><b>PerformRx makes the following recommendation:</b></p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p><b>Committee approved as recommended</b></p> <p><b>Motion:</b> Donald Cooper  <b>Second:</b> Tracey Davis</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] <b>CHC:</b></p> <ul style="list-style-type: none"> <li>• Approve the Kuvan prior authorization criteria with no changes</li> </ul> <p>[REDACTED]</p>			
<p>linezolid (Zyvox)</p>	<p><b>PerformRx makes the following recommendation:</b></p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] <b>CHC:</b></p>	<p><b>Committee approved as recommended</b></p> <p><b>Motion:</b> Donald Cooper <b>Second:</b> Tracey Davis</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<ul style="list-style-type: none"> <li>• Approve the Linezolid (Zyvox) prior authorization criteria with no clinical changes</li> </ul> <p>[Redacted]</p>			
<p>[Redacted]</p>	<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	<p>[Redacted]</p> <p>[Redacted]</p>		<p>[Redacted]</p>
<p>Multaq.</p>	<p><b>PerformRx makes the following recommendation:</b></p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	<p><b>Committee approved as recommended</b></p> <p><b>Motion:</b> Donald Cooper <b>Second:</b> Tracey Davis</p>		<p>No Changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] <b>CHC:</b></p> <ul style="list-style-type: none"><li>• Approve the Multaq prior authorization criteria with no clinical changes</li></ul> <p>[REDACTED]</p>			
<p>Non-preferred/Prior Authorization Required Medications Criteria</p>	<p><b>PerformRx makes the following recommendation:</b></p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p><b>Committee approved as recommended</b></p> <p><b>Motion:</b> Donald Cooper <b>Second:</b> Tracey Davis</p>		<p>No Changes</p>



	<p>[REDACTED]</p> <p><b>CHC:</b></p> <ul style="list-style-type: none"> <li>Approve the Non-Preferred/Prior Authorization Required Medications with no clinical changes</li> </ul> <p>[REDACTED]</p>			
<p>Off Label Uses</p>	<p><b>PerformRx makes the following recommendation:</b></p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p><b>CHC:</b></p> <ul style="list-style-type: none"> <li>Approve the Off-Label Uses Criteria with no changes clinical changes</li> </ul> <p>[REDACTED]</p>	<p><b>Committee approved as recommended</b></p> <p><b>Motion:</b> Donald Cooper <b>Second:</b> Tracey Davis</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p>			
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>
<p>Peanut Allergy Immunotherapy Agents (FDA Approved)</p>	<p><b>PerformRx makes the following recommendation:</b></p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p><b>Committee approved as recommended</b></p> <p><b>Motion:</b> Donald Cooper <b>Second:</b> Tracey Davis</p>		<p>No Changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] <b>CHC:</b></p> <ul style="list-style-type: none"><li>• Approve the Peanut Allergy Immunotherapy Agents (FDA Approved) criteria with no changes</li></ul> <p>[REDACTED]</p>			
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>			
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>


	[REDACTED]			
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]

	<p>[REDACTED]</p> <p>[REDACTED]</p>			
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>			
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>

[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]
[REDACTED]				
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]



				
<b>11. Recalls</b>	No Recalls	Informational		PerformRx
<b>12. Adjourn</b>	<b>The meeting adjourned at 7:39</b>	N/A		Bruce Himelstein
	<b>The next meeting July 25, 2022</b>			



\_\_\_\_\_  
Bruce Himelstein MD MBA  
VP, Utilization Management Physician

August 3, 2022

\_\_\_\_\_  
Date